NEWLY DIAGNOSED NEOPLASIA IN CROHN DISESE PATIENTS TREATED WITH INFLIXIMAB;A 1 YEAR LONGER FOLLOW UP FROM A MULTICENTER MATCHED PAIR STUDY

1. Inflamm Bowel Dis. 2011 Mar;17(3):758-66. doi: 10.1002/ibd.21416. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F, Papi C, Meucci G, Riegler G, Sica G, Rizzello F, Mocciaro F, Onali S, Calabrese E, Cottone M, Pallone F. GI Unit, University, Tor Vergata, Roma. biancone@med.uniroma2.it BACKGROUND: The long-term risk of neoplasia in Crohn's disease (CD) patients treated with infliximab is undefined. The aim was to assess, in a multicenter, matched-pair study, whether infliximab use in CD is associated with an increased f…

Appropriateness of immunosupprerssive drugs in inflammatory bowel disease assessed by RAND method :Italian group for IBD position statement

Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study

Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (±5 years), site of CD, age at diagnosis (±5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX…

Infliximab in the treatment of steroid resistant dependant and fistulating crohn's disease:an analysis of predictors of response in an italian multicenter open study in 573 pts